CaseTrail

Sandoz Inc. v. Amgen Inc.

137 S. Ct. 1664 · Decided June 12, 2017 · Supreme Court of the United States

Record summary. This page is generated from the Supreme Court Database’s coded data about the case. It describes who decided what, not the Court’s reasoning. Read the opinion itself before relying on it. Not legal advice.

At a glance

Sandoz Inc. v. Amgen Inc. was decided on June 12, 2017 unanimously (9–0). The Court reversed the lower court's decision and remanded the case. Justice Clarence Thomas wrote the opinion of the Court. SCDB classifies its main issue as “Patents” in the Economic Activity area.

Read the opinion

Case details

Citations
137 S. Ct. 1664 · 198 L. Ed. 2d 114 · 2017 U.S. LEXIS 3723
Docket number
15-1039
Decided
June 12, 2017
Argued
April 26, 2017
Court era
Roberts Court
Decision type
Opinion of the Court (orally argued)
Disposition
Reversed and remanded
Outcome for petitioner
The petitioning party received a favorable disposition
Vote
9–0 (unanimous)
Majority opinion
Clarence Thomas
Opinion assigned by
John G. Roberts Jr.
How the case arrived
Certiorari
Issue (SCDB)
Patents
Legal provision
Biologics Price Competition and Innovation Act, 42 USC 262
Type of law
Infrequently litigated statute
Decision direction (SCDB)
Liberal what this means

How the Justices voted

Full case caption

Sandoz Inc. v. Amgen Inc.

SCDB identifiers: case 2016-074, docket 2016-074-01.

Other cases on “Patents”

See all

Same Term, same area (Economic Activity)

See all

Source: Supreme Court Database, 2026 Release 01 (data file dated September 8, 2026). Imported into CaseTrail November 5, 2026. Coverage: decisions from the 1946 through 2025 Terms. Methodology · Report an error